For example, loss of PTEN is associated with progression of prostate cancers from the androgen-dependent to the more aggressive androgen-independent phenotypes, resistance to chemo- and radiation therapies, tumour metastasis, recurrence post-surgery, and significant overall poor prognosis for patients [118]. This evidence concerns the gene PTEN and neoplasm.